This is an old revision of this page, as edited by Beetstra (talk | contribs) at 12:25, 23 November 2011 (Saving copy of the {{drugbox}} taken from revid 456658868 of page Lubiprostone for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 12:25, 23 November 2011 by Beetstra (talk | contribs) (Saving copy of the {{drugbox}} taken from revid 456658868 of page Lubiprostone for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)This page contains a copy of the infobox ({{drugbox}}) taken from revid 456658868 of page Lubiprostone with values updated to verified values. |
Clinical data | |
---|---|
Trade names | Amitiza |
Other names | Amitiza RU-0211 SPI-0211 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607034 |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Negligible |
Protein binding | 94% |
Metabolism | Extensive, CYP not involved |
Elimination half-life | Unknown (lubiprostone) 0.9–1.4 hours (main metabolite) |
Excretion | Renal (60%) and fecal (30%) |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C20H32F2O5 |
Molar mass | 390.462 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |